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Human papillomavirus (HPV) detected in restored plasma DNA from
women diagnosed with pre-invasive lesions and invasive cervical cancer
YAZMÍN ROCÍO ARIAS, MSC1,2, EDWARD FABIÁN CARRILLO, PhD1, FABIO ANCÍZAR ARISTIZÁBAL, PhD1
SUMMARY
Objective: To improve the sensitivity of Human Papillomavirus (HPV) detection in plasma from high-grade cervical
neoplasia patients (CIN III) and cervical cancer (CC) evaluating any likely correlation with disease stage.
Method: We subjected plasma DNA isolates from 112 patients (CIN and ICC) to a pre-PCR restoration treatment to improve
detection sensitivity. HPV-specific sequences were detected by conventional PCR both in cervical scrapes and plasma DNA
obtained from each patient. For every single DNA sample, both non-restored and restored isolates were PCR analyzed.
Results: We detected HPV in plasma DNA isolates with significantly higher efficiency on restored plasma-DNA as
compared to each non-restored equivalent, still maintaining close correlation with the clinical stage of the cases. By analyzing
plasma-DNA isolates we could classify as HPV positive >50.0% of the cases that were previously known to be positive from
the cervical scrape based assay. Interestingly, 100% of the cases in which subtype HPV18 was detected in cervical scrapes
were also positive in plasma DNA.
Conclusions: Restoration of plasma DNA from cervical cancer patients allows a more sensitive PCR-based HPV detection,
maintaining the correlation to disease stage traditionally observed.
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Detección del virus del papiloma humano (VPH) en ADN de plasma restaurado de mujeres en quienes se diagnostica-
ron lesiones pre-invasivas y cáncer cervical invasivo
RESUMEN
Objetivo: Mejorar la sensibilidad y la detección del virus del papiloma humano (VPH) en el plasma de pacientes con
neoplasias intraepiteliales de alto grado (NIEAG) y cáncer de cuello uterino (CCU) para evaluar si existe una relación con el
estadío de la enfermedad.
Método: Los ADN de plasma aislados de 112 pacientes (NIC y CCU) se sometieron a restauración mediante reacción de
la polimerasa en cadena (siglas en inglés, PCR), para mejorar su calidad como sustrato para PCR. En cada paciente se detectaron
secuencias específicas del VPH por PCR convencional, tanto en exudados cérvico-vaginales como en ADN del plasma. Por
cada muestra se analizaron por PCR, cantidades equivalentes del ADN aislado, tanto no restaurado como restaurado.
Resultados: Para las muestras pareadas se pudo detectar VPH en ADN de plasma de forma más eficiente en los materiales
restaurados, pues se mantuvo una estrecha correlación con el estadío clínico de los casos. Mediante el análisis de ADN de
plasma es posible detectar como VPH positivas más de 50% de los casos que se identificaron previamente como positivos
en citología de cuello uterino. Se enfatiza el hecho que 100% de los casos en los que el subtipo VPH18 fue descubierto en
exudado cérvico-vaginal también fueron positivos en el ADN de plasma.
Conclusiones: El proceso de restauración de ADN de plasma de pacientes con cáncer de cuello uterino permite mejorar
la detección de VPH, por PCR, y mantener la correlación con el estadío de la enfermedad.
Palabras claves: Cáncer de cuello uterino; VPH; Neoplasia intra-cervical (NIC); ADN de plasma.
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Cervical cancer (CC) is the second most prevalent
cancer among females around the world1. CC is the
major oncological problem in Colombia with an annual
incidence of 36.4 new cases per 100,000 females
(IARC, 2002). More than 80% of the patients have
advanced tumors when they are diagnosed, whilst only
20% of cases are diagnosed at stage I2,3. Human
papillomavirus (HPV), the main associated pathogenic
agent, is present in 90%-100% of the cases and is
believed to be a necessary, although not sufficient cause
for the development of invasive cervical carcinomas4.
On the other hand, previous studies have established
that human blood plasma from cancer patients contains
increased amounts of nucleic acids whose origin and
release mechanism are not yet clear5,6.
Reports concerning HPV detection in plasma or sera
from CC patients have yielded varying results so that
reported plasma DNA detected concentrations span a
wide range of values7-9. Bonin et al., demonstrated that
DNA quality from archival clinical samples can be
significantly improved by a pre-PCR restoration
treatment, providing better amplification efficiencies10.
In a previous work, we found this strategy to be useful
for the detection of a human single-copy gene in DNA
isolates from archived plasma samples11. Since plasma
from cervical cancer patients contains detectable
quantities of HPV-specific DNA9,12,13, we decided to
evaluate the effect of applying the restoration treatment
to plasma DNA isolates from CIN III and CC patients
on the HPV detection frequency. HPV is detected at a
very high frequency by PCR (close to 100%) in these
kinds of patients taking cervical scrapes as the source of
template DNA. However, most of articles focused on
detection in plasma DNA show a lower and variable
detection rate14,15, suggesting that different sample
processing, preservation and/or different detection
technologies can influence the results.
MATERIALS AND METHODS
Study population. In this study, 112 cases diagnosed
at two third-level hospitals in Bogotá, Colombia, were
included. None of them had started any type of treatment
before being asked to participate in the study. Samples
were collected during 2004 and 2005. The whole study
and the consent form were prepared according to the
Colombian Ministry of Health Resolution 008430, and
approved by the ethics committees of both participant
health institutions and the research committee of the
Faculty of Science at Universidad Nacional de Colom-
bia.
Patient age ranged from 22 to 84 years (average
age=50 years). Most patients were between 41 and 50
years of age (32.1%); while the group between 51 and
60 years of age included 24.1% of the patients. 43.8%
of these women had only one sex partner, while 28.6%
declared 2-3 and 18.8% reported more than 4 partners.
Among our group we observed an average of 5
pregnancies.
Their histopathological diagnosis revealed 25 cases
(22.3%) as CIN III, 85 cases (75.9%) as squamous cell
cancer stages I to IV and 2 cases (1.8%) diagnosed as
adenocarcinoma stage IIIB. Twenty healthy controls
were chosen among women with negative cytological
results at the time of sampling.
Sample collection and DNA isolation. Every patient
and healthy control provided two samples: a cervical
scrape and a blood sample. Cervical scrapes and
Peripheral blood samples were collected and immediately
processed as previously described2,11. Both cervical
scrape and plasma samples were extracted by using a
QIAamp DNA Mini Kit (QIAGEN; Valencia, CA,
USA) following the manufacturer’s instructions.
However, for plasma samples the protocol was modified
by adding 1 µl glycogen (SIGMA, Milwaukee, WI,
USA) along with the Ethanol aliquot indicated at the step
just before column loading. DNA was finally eluted with
100 µl of AE buffer.
Pre-PCR restoration treatment. Before PCRs
were carried out, each DNA isolate was subjected to a
pre-PCR restoration treatment, as previously reported11,
to improve PCR sensitivity when detecting HPV specific
sequence. Detection results obtained by PCR on restored
and non-restored plasma DNA isolates from 10 patients
were compared to determine the convenience of this
treatment. Genes amplified at this point were the human
β-globin gene (HBB) and the viral L1 gene, which
provided a tool for the generic (non-subtype specific)
detection of HPV.
Evaluating DNA quality. The integrity of DNA
from cervical scrape and plasma samples was evaluated
by amplification of a 171-bp fragment from the HBB
gene as DNA quality indicator. Primer sequences for
DNA quality assessment were as follows:
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Glo1: 5’-AGCAACCTCACAAACAGACACC-3’
Glo2: 5’-CTACACATGCCCAGTTTC-3’
PCR reactions were carried out in a final volume of
25 µl with the following reagent concentrations: 10 mM
Tris-HCl (pH 9.0 at 25°C), 50 mM KCl and 0.1%
Triton® X-100, 3 mM MgCl2, 0.2 mM each dNTP, 0.3
µM of both direct and reverse primers, and 1 U of Taq
DNA polymerase. All reagents were purchased from
the same manufacturer (PROMEGA, Madison, WI,
USA).
The reactions were carried out in a My Cycler
thermal cycler (BIORAD, Hercules CA, USA) with the
following protocol: 3 min at 94 ºC, followed by 35
amplification cycles of 94 ºC for 20 sec, 58 ºC for 20 sec
and 72 ºC for 20 sec, and a final elongation step at 72 ºC
for 5 min. Peripheral Blood Lymphocytes DNA was
used as positive control.
PCR for HPV. Generic HPV was assayed only in
DNA isolates from cervical scrapes and restored plas-
ma DNAs returning positive results for the HBB gene.
Generic HPV detection was accomplished by PCR
using GP5+/GP6+ primers, following a procedure already
described16.
Figure 1. HBB detection on plasma DNA isolates from CC patients before and after the pre-PCR treatment.
Equivalent molar amounts of non-restored (panel A) and restored plasma DNA from 10 ICC patients (panel
B) were PCR amplified for the HBB gene under the same reagent and cycling conditions. The products
were run in a 2% Agarose (1X TBE) and analyzed with the Quantity One software (BIO-RAD, Philadelphia,
PA, USA). Non-restored and restored DNA PCR products from the same patient appear in the same column.
Lanes marked with (+) and (-) in panel B are a positive and a negative control for HBB detection,
respectively. Fragment size is 171 bps.
After generic HPV detection, subtypes 16 and 18
were specifically detected with primers targeted for the
HPV E6/E7 region previously described14. Each primer
set allowed clear detection of its target sequence when
using 100 picograms of control plasmid (pBR322/HPV16
or pBR322/HPV18). The length of the segments
amplified were 100 bp for HPV16 and 126 bp for
HPV18.
RESULTS
Plasma DNA restoration and PCR detection. We
evaluated DNA quality improvement by trying the
procedure on plasma DNA from 10 CC cases and
comparing amplification results for HBB on treated and
non-treated DNA. Amplification efficiency was
notoriously increased by the treatment, as judged by
observed band intensities (Figure 1). Density analysis in
Figure 2A shows that band intensity measurements
after restoration have lesser inter-sample variability
than values without treatment. This change is observed
because the general tendency is that samples with low
initial detection levels showed greater increases upon
restoration than those with initial high values. Similar
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results were observed regarding HPV generic detection,
as shown in Figure 2B. Detection sensitivity was also
improved when using GP5+/GP6+ primers for the L1
region in the viral genome. Interestingly, in this group of
samples, only two were detected as HPV positive when
non-restored DNA was assayed (samples 44 and 92),
the assay performed on the corresponding restored
isolates confirmed theses results and allowed viral
detection in 2 more samples (samples 49 and 99). So, the
restoration treatment allowed the classification as positive
of two samples considered negative at the first assay.
Detecting HPV in cervical scrapes and plasma
samples. DNA quality in both plasma and cervical
scrape isolates was evaluated by amplification of a
single-copy gene (HBB). Good-quality DNA from both
plasma and cervical scrape was obtained only from 107
out of 112 cases, 5 were discarded. HPV was assayed
in 107 cervical scrapes. Prevalence found was 95.3%
(102/107). Among these samples there were 25 cases
diagnosed as CIN III. When cervical scrapes from them
were assayed for HPV, 23 could be classified positive
(92%). On the other hand, HPV could be detected in
48.6% of the corresponding plasma DNA isolates (52/
107). As expected, viral detection in plasma DNA is less
efficient than in cervical scrapes.
If only cases positively detected in cervical scrapes
are considered (102 cases), the subgroup of cases also
found positive for HPV in plasma DNA (restored
DNA) is 51%. Next, we assayed our samples specifically
for HPV 16 and 18 in scrapes and plasma. When the 102
HPV-positive cervical scrapes were assayed, 55 of
them resulted HPV-16 positive (54%). HPV-18
Figure 2. Effect of the pre-PCR plasma DNA restoration treatment on detection sensitivity for HBB (panel
A) and HPV L1 region (panel B). Dashed squares indicate relative band density obtained from non-restored
plasma DNA templates, while vertical lines represent the amplification efficiency increase obtained when
the template DNA was subjected to the pre-PCR restoration treatment. Quantitative data were generated
by image analysis with the Quantity One software (BIO-RAD, Philadelphia, PA, USA). Equivalent amounts
of restored and non-restored DNA were used maintaining all other variables uniform.
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prevalence was only 8.8% among our cases (9 cases),
a result closely resembling findings by Molano et al.3.
Also, viral types detected in plasmas always resembled
the types previously found in matched cervical scrapes.
In no case we detected any viral subtype in plasma not
previously demonstrated in the corresponding cervical
scrape. HPV 18 is the predominant HPV type in
adenocarcinomas17. Our pool of samples included only
two invasive adenocarcinoma cases, both of which
were HPV-18 positive. After restoration, HPV 16 was
detected in plasma in 30 of the 52 HPV-positive cases
(57.7%). HPV18 was detected in plasma with the same
frequency it was detected in cervical scrapes (100%).
None of the 20 control cases, healthy women with
negative cytology, yielded positive HPV detection when
their scrape and plasma DNA isolates were assessed.
The clinical stage of the disease and HPV detection
in plasma DNA. Generic HPV was detected in plasma
DNA in 51% of ICC cases, in 2 available adenocarcinoma
cases, and in 27.3% of patients suffering from high-
degree CIN III. Table 1 shows the prevalence of HPV
in plasma DNA isolates from all the cases assayed
according to the clinical stage. HPV prevalence was
proportionally higher in those cases having greater
disease grade as confirmed by the χ2 test.
DISCUSSION
HPV is one of the main factors associated to cervical
cancer development4; however, variable detection
frequencies have been reported in cell scrapes or
cervical biopsy-based studies, generally between 75 and
100%18-20. We found a very high HPV prevalence
among our cases since generic detection, based on the
detection by PCR of the L1 region of the viral genome
in cervical scrapes, resulted positive in 95.3% of the
cases (102 out of 107 cases). Our results regarding both
for generic (all subtypes) and specific (subtypes 16 and
18) detection in cervical scrapes are similar to previous
studies by Molano et al.2,3. In addition, those studies
reported high-risk HPV 56, 58 and low-risk 81 as the
most prevalent types performed also in Colombian
women with negative cytology, all of them at frequencies
higher than HPV 16. Here we found that HPV 16 is
present at a significant frequency when abnormal growth
occurs in CIN III and CC patients.
Based on our previously published results concerning
the convenience of plasma DNA restoration to improve
its quality as PCR template11, we decided to apply this
procedure to detect HPV-specific sequences on plasma
DNA isolates from cervical cancer patients. The
procedure proved to notably increase HPV detection
sensitivity in four out of ten test samples, two of which
had been classified as negative when the restoration
treatment had not been included. Based on these results,
we decided to apply the restoration treatment to the 112
plasma DNA isolates included in the study. In most of
the previous reports where HPV is detected by
conventional PCR in matched plasma DNA and tumor
DNA isolates, the detection rate in plasma ranges
between 6.9%-20% of all HPV positive cases9,12. The
procedure presented here provides an increased detection
rate of >50%. However, we mention a report by Dueñas
et al.21 and another by Wei et al.22, reporting that the
virus was detected in plasma samples in 70% and 65%,
respectively, of the cases where tumors were confirmed
positive. The second study refers to a small number of
patients (17 patients). In order to maintain costs as low
as possible for a possible HPV-detection clinical assay,
this study was limited to a conventional PCR analysis;
nevertheless, it is a logical consequence that performing
these analysis by real-time PCR could improve sensitivity
and detection rate in restored plasma DNA. In no case
did we detect HPV in plasma DNA not having detected
it in the corresponding cervical scrape.
As stated above, 52 cases were HPV positive when
the generic test was performed on plasma DNA isolates.
HPV 16 was specifically detected in 30 of these cases
(57.7%). Considering our global results, HPV-16
detection on restored plasma DNA was approximately
half as efficient as the detection in scrapes. Interestingly,
Table 1
HPV detection frequency vs. clinical stage
  Stage                     HPV in plasma (%)
                      Positive          Negative
CIN III  n=22 6 (27.3) 16 (72.7)
ICC I    n=15 4 (26.7) 11 (73.3)
ICC II   n=22 11 (50.0) 11 (50.0)
ICC III   n=38 22 (58.0) 16 (42.0)
ICC IV  n=10 9 (90.0) 1 (10.0)
χ2 p = 0.008
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HPV18 was detected in plasma with the same frequency
observed in cervical scrapes. Nine cases previously
found to be positive, based on cervical scrapes were
also shown as positive when assayed in plasma DNA.
When analyzing plasma DNA isolates from patients
presenting metastasis (15 cases), we found 12 of them
positive for generic HPV (80%) and 8 of them positive
for HPV 16. Three remaining cases were HPV negative
at the time of the study.
Finally, we were interested in the frequency of mixed
HPV 16/18 infections among our samples. Simultaneous
presence of HPV 16 and 18 types was identified only in
4 cases when cervical scrape DNA was assayed.
However, mixed infection could be demonstrated only in
2 of them when corresponding plasma DNA isolates
was analyzed. Interestingly, HPV 18 was the type
detected in both scrape and plasma from these four
cases; while in two cases, HPV 16 could only be
detected in the scrape. This fact could suggest different
release rates of viral DNA to the plasma between types.
One could hypothesize that viral DNA integration into
the host genome is a condition promoting its detection by
PCR in plasma DNA. It would be released along with
the host genomic DNA, being subjected to the same
degradation processes. But this idea must be tested.
HPV detection in restored plasma DNA clearly
increased as the disease’s progression level increased;
27.3% positivity was found in high-grade pre-neoplastic
lesions (CIN III); whilst it reached 90% in patients
suffering from stage IV ICC. Regarding early stages,
one could hypothesize that HPV is actually present in
the remaining CIN III, HPV-negative cases although at
doses below the detection limit. Even though the real
time PCR is a good alternative, implementation of new,
more sensitive and low cost detection techniques will be
an important objective if HPV detection in blood is to be
applied on very early neoplastic stages (CIN I and II) or
even screening programs on healthy women.
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